Omicron Subvariants, Including BA.4 and BA.5, Substantially Preserve T Cell Epitopes of Ancestral SARS-CoV-2.

IF 4.3 4区 医学 Q2 IMMUNOLOGY
Immune Network Pub Date : 2022-08-03 eCollection Date: 2022-08-01 DOI:10.4110/in.2022.22.e29
Kyemyung Park, Seung Jin Choi, Eui-Cheol Shin
{"title":"Omicron Subvariants, Including BA.4 and BA.5, Substantially Preserve T Cell Epitopes of Ancestral SARS-CoV-2.","authors":"Kyemyung Park, Seung Jin Choi, Eui-Cheol Shin","doi":"10.4110/in.2022.22.e29","DOIUrl":null,"url":null,"abstract":"https://immunenetwork.org The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants (B.1.1.529 and related) that emerged in November 2021 have spread worldwide, and are designated a variant of concern by the World Health Organization (WHO) (1). They have become the dominant strains, comprising >99% of newly deposited SARS-CoV-2 sequences in GISIAD (www. gisaid.org) as of May 16, 2022 (2). Following the emergence of B.1.1.529 (BA.1), BA.2 (often called stealth Omicron) soon became the most prevalent sublineage worldwide. Subsequent subvariants, including BA.2.9, BA.2.12.1, BA.4, and BA.5, are now rapidly dominating the circulating Omicron subvariants in originating regions, and are beginning to spread globally (2). The dominance of Omicron variants and their rapid evolution into various subvariants have raised concerns regarding the effects of the immunity elicited by natural infection or vaccination. As evolution continues, the variants’ spike proteins exhibit higher affinities toward ACE2, and/ or increasing capacity for evading preformed neutralizing antibodies induced by previous natural infection or vaccination (3-5). These changes are consistent with increased breakthrough infections and re-infections with Omicron variants (6,7).","PeriodicalId":13307,"journal":{"name":"Immune Network","volume":"22 4","pages":"e29"},"PeriodicalIF":4.3000,"publicationDate":"2022-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9a/2e/in-22-e29.PMC9433189.pdf","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immune Network","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4110/in.2022.22.e29","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/8/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 6

Abstract

https://immunenetwork.org The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants (B.1.1.529 and related) that emerged in November 2021 have spread worldwide, and are designated a variant of concern by the World Health Organization (WHO) (1). They have become the dominant strains, comprising >99% of newly deposited SARS-CoV-2 sequences in GISIAD (www. gisaid.org) as of May 16, 2022 (2). Following the emergence of B.1.1.529 (BA.1), BA.2 (often called stealth Omicron) soon became the most prevalent sublineage worldwide. Subsequent subvariants, including BA.2.9, BA.2.12.1, BA.4, and BA.5, are now rapidly dominating the circulating Omicron subvariants in originating regions, and are beginning to spread globally (2). The dominance of Omicron variants and their rapid evolution into various subvariants have raised concerns regarding the effects of the immunity elicited by natural infection or vaccination. As evolution continues, the variants’ spike proteins exhibit higher affinities toward ACE2, and/ or increasing capacity for evading preformed neutralizing antibodies induced by previous natural infection or vaccination (3-5). These changes are consistent with increased breakthrough infections and re-infections with Omicron variants (6,7).

Abstract Image

包括BA.4和BA.5在内的组粒亚变体大量保留了祖先SARS-CoV-2的T细胞表位。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Immune Network
Immune Network Immunology and Microbiology-Immunology
CiteScore
2.90
自引率
3.30%
发文量
36
期刊介绍: Immune Network publishes novel findings in basic and clinical immunology and aims to provide a medium through which researchers in various fields of immunology can share and connect. The journal focuses on advances and insights into the regulation of the immune system and the immunological mechanisms of various diseases. Research that provides integrated insights into translational immunology is given preference for publication. All submissions are evaluated based on originality, quality, clarity, and brevity
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信